Research analysts at UBS Group began coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) in a note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $111.00 price target on the stock. UBS Group’s price objective indicates a potential upside of 18.06% from the stock’s previous close.
Other research analysts have also issued research reports about the stock. Royal Bank of Canada initiated coverage on shares of Axsome Therapeutics in a report on Thursday, January 25th. They issued an “outperform” rating and a $126.00 price objective for the company. Citigroup initiated coverage on shares of Axsome Therapeutics in a report on Wednesday, December 13th. They set a “buy” rating and a $125.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $108.00 price objective on shares of Axsome Therapeutics in a research note on Monday, January 22nd. Piper Sandler raised their target price on Axsome Therapeutics from $90.00 to $113.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $180.00 price target on shares of Axsome Therapeutics in a research report on Tuesday, December 26th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, Axsome Therapeutics has an average rating of “Moderate Buy” and an average price target of $113.10.
Axsome Therapeutics Stock Down 0.8 %
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last posted its earnings results on Monday, November 6th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.24) by ($0.08). The firm had revenue of $57.79 million during the quarter, compared to the consensus estimate of $54.88 million. Axsome Therapeutics had a negative net margin of 90.33% and a negative return on equity of 88.79%. During the same quarter in the prior year, the business posted ($1.03) earnings per share. As a group, sell-side analysts anticipate that Axsome Therapeutics will post -4.14 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Axsome Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. increased its stake in shares of Axsome Therapeutics by 1.3% in the 4th quarter. Principal Financial Group Inc. now owns 9,497 shares of the company’s stock valued at $756,000 after acquiring an additional 120 shares in the last quarter. AQR Capital Management LLC grew its holdings in Axsome Therapeutics by 1.7% in the first quarter. AQR Capital Management LLC now owns 8,825 shares of the company’s stock worth $544,000 after purchasing an additional 148 shares during the period. Ameritas Investment Partners Inc. increased its stake in Axsome Therapeutics by 6.0% in the second quarter. Ameritas Investment Partners Inc. now owns 2,717 shares of the company’s stock valued at $195,000 after purchasing an additional 153 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Axsome Therapeutics by 21.8% during the second quarter. Tower Research Capital LLC TRC now owns 993 shares of the company’s stock valued at $71,000 after purchasing an additional 178 shares during the period. Finally, Raymond James Financial Services Advisors Inc. boosted its position in shares of Axsome Therapeutics by 1.1% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 18,734 shares of the company’s stock worth $1,309,000 after purchasing an additional 197 shares in the last quarter. 76.60% of the stock is currently owned by institutional investors.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
- Five stocks we like better than Axsome Therapeutics
- The Significance of Brokerage Rankings in Stock Selection
- What are specialty REITs? How to invest in them
- Canada Bond Market Holiday: How to Invest and Trade
- Miso Robotics stock: Is an IPO coming soon?
- Where to Find Earnings Call Transcripts
- Insiders are selling these hot stocks on track for higher prices
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.